CA2575902C - Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide - Google Patents

Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide Download PDF

Info

Publication number
CA2575902C
CA2575902C CA2575902A CA2575902A CA2575902C CA 2575902 C CA2575902 C CA 2575902C CA 2575902 A CA2575902 A CA 2575902A CA 2575902 A CA2575902 A CA 2575902A CA 2575902 C CA2575902 C CA 2575902C
Authority
CA
Canada
Prior art keywords
interleukin
alpha
cancer
group
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2575902A
Other languages
English (en)
French (fr)
Other versions
CA2575902A1 (en
Inventor
Felix Wehrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/505,439 external-priority patent/US5728707A/en
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of CA2575902A1 publication Critical patent/CA2575902A1/en
Application granted granted Critical
Publication of CA2575902C publication Critical patent/CA2575902C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2575902A 1995-07-21 1996-07-18 Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide Expired - Fee Related CA2575902C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/505,439 US5728707A (en) 1995-07-21 1995-07-21 Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US08/505,439 1996-07-18
US08/684,297 US5861406A (en) 1995-07-21 1996-07-18 Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
US08/684,297 1996-07-18
CA002227205A CA2227205C (en) 1995-07-21 1996-07-18 Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002227205A Division CA2227205C (en) 1995-07-21 1996-07-18 Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles

Publications (2)

Publication Number Publication Date
CA2575902A1 CA2575902A1 (en) 1997-02-06
CA2575902C true CA2575902C (en) 2010-06-08

Family

ID=27055145

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2575902A Expired - Fee Related CA2575902C (en) 1995-07-21 1996-07-18 Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide
CA002227205A Expired - Fee Related CA2227205C (en) 1995-07-21 1996-07-18 Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002227205A Expired - Fee Related CA2227205C (en) 1995-07-21 1996-07-18 Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles

Country Status (10)

Country Link
US (2) US5912346A (cg-RX-API-DMAC7.html)
EP (1) EP0840608B1 (cg-RX-API-DMAC7.html)
JP (2) JP4422796B2 (cg-RX-API-DMAC7.html)
CN (1) CN1318029C (cg-RX-API-DMAC7.html)
AT (1) ATE278399T1 (cg-RX-API-DMAC7.html)
AU (1) AU725035B2 (cg-RX-API-DMAC7.html)
CA (2) CA2575902C (cg-RX-API-DMAC7.html)
DE (1) DE69633566T2 (cg-RX-API-DMAC7.html)
IL (1) IL122782A (cg-RX-API-DMAC7.html)
WO (1) WO1997003668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
JP2002532535A (ja) * 1998-12-22 2002-10-02 アメリカ合衆国 水不溶性薬剤送達システム
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
CA2412362A1 (en) * 2000-06-20 2001-12-27 Arthur L. Heerbst Cox-2 inhibitors and the prevention of the side effects of radiation therapy
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
NZ567457A (en) 2002-12-13 2009-08-28 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
US7449462B2 (en) 2004-01-22 2008-11-11 Pfizer, Inc. Triazole derivatives which inhibit vasopressin antagonistic activity
US7276050B2 (en) * 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
WO2005105779A1 (en) * 2004-04-28 2005-11-10 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
KR100615277B1 (ko) 2004-08-18 2006-08-25 엠텍비젼 주식회사 이미지 센서에서의 렌즈 셰이딩 현상 보정 방법 및 장치
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
KR20090092307A (ko) 2006-12-22 2009-08-31 레코르다티 아일랜드 리미티드 하요도 장애에 대한 α2δ 리간드 및 ＮＳＡＩＤｓ의 복합 치료
US8146798B2 (en) 2008-11-07 2012-04-03 Advanced Custom Engineered Systems & Equipment Co. Method and apparatus for monitoring waste removal and administration
RU2405833C2 (ru) * 2008-12-26 2010-12-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП ГосНИИгенетика) Способ микробиологического синтеза пуринового нуклеозида 5'-аминоимидазол-4-карбоксамидрибозида (аикар) и штамм бактерий bacillus subtilis - продуцент аикар
US8912223B2 (en) 2009-09-04 2014-12-16 Tactical Therapeutics Inc Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
EP2963023B1 (en) * 2009-09-04 2018-04-18 Tactical Therapeutics, Inc. Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives
ES2382167T3 (es) 2009-09-25 2012-06-06 Iasomai Aktiebolag N-acetil-L-cisteína para el tratamiento de endometriosis
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
US10378059B2 (en) * 2013-08-02 2019-08-13 Tactical Therapeutics, Inc. Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
PT3164394T (pt) 2014-07-03 2020-05-08 Univ Texas Inibidores gls1 para o tratamento de doenças
AU2016287661B2 (en) 2015-06-30 2020-07-16 Board Of Regents, University Of Texas System GLS1 inhibitors for treating disease
KR102777513B1 (ko) 2015-12-22 2025-03-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 (ｒ)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-ｎ-메틸-1ｈ-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
CN109906082A (zh) 2016-09-07 2019-06-18 塔夫茨大学信托人 使用免疫dash抑制剂和pge2拮抗剂的组合治疗
WO2019079632A1 (en) 2017-10-18 2019-04-25 Board Of Regents, The University Of Texas System GLUTAMINASE INHIBITOR THERAPY
CN116854644B (zh) * 2023-07-06 2025-10-21 浙江大学 5-氨基-1-烷基-1h-1,2,3-三氮唑-4-甲酰胺类化合物及其制备和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210865B (de) * 1962-03-05 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung des 2, 6-dioxo-tetrahydropyrimidin-4-carbonsauren Salzes des 4-Amino-5-imidazolcarbonsaeureamids
DE1227190B (de) * 1962-08-02 1966-10-20 Fujisawa Pharmaceutical Co Verfahren zur Herstellung von haltbaren und injizierbaren Loesungen der Salze des 4-Amino-5-imidazolcarboxamids mit organischen Saeuren
US3997518A (en) * 1970-12-09 1976-12-14 Beecham Group Limited 2-Alkyl-4-carboxyalkyl-5-(3,3'-dimethyltriazeno)-imidazoles
JPS5283750A (en) * 1976-01-01 1977-07-12 Ajinomoto Co Inc Crystals of 5-amino-4-imidazol-carboxyamide
RO70184A2 (ro) * 1976-12-30 1981-08-30 Institutul Oncologic,Ro Procedeu de preparare a clorhidratului de 4(5)-amino-5(4)imidazol carboxamida
HUT36464A (en) * 1983-05-24 1985-09-30 Newport Pharmaceuticals Process for producing erythro-4-amino-3-/2-hydroxy-3-alkyl/-imidazol-5-carboxamide
HU190597B (en) * 1983-07-11 1986-09-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing synrtgetic pharmaceutical compositions
US4590201A (en) * 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
US4752611A (en) * 1985-11-29 1988-06-21 Merck & Co., Inc. Anticoccidial 1,2,3-trazole compounds
US4847257A (en) * 1987-08-20 1989-07-11 Merck & Co., Inc. 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents
US4923885A (en) * 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
US5498620A (en) * 1989-05-19 1996-03-12 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor 1,2,3-triazolo compounds
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide

Also Published As

Publication number Publication date
CA2227205C (en) 2007-05-01
AU725035B2 (en) 2000-10-05
EP0840608A1 (en) 1998-05-13
CA2227205A1 (en) 1997-02-06
US5912346A (en) 1999-06-15
DE69633566D1 (de) 2004-11-11
US6239137B1 (en) 2001-05-29
DE69633566T2 (de) 2005-12-08
JP4422796B2 (ja) 2010-02-24
ATE278399T1 (de) 2004-10-15
WO1997003668A1 (en) 1997-02-06
IL122782A0 (en) 1998-08-16
CN1191485A (zh) 1998-08-26
IL122782A (en) 2003-03-12
JP2008120827A (ja) 2008-05-29
CA2575902A1 (en) 1997-02-06
EP0840608A4 (en) 2002-10-02
JP4842286B2 (ja) 2011-12-21
EP0840608B1 (en) 2004-10-06
AU6549696A (en) 1997-02-18
CN1318029C (zh) 2007-05-30
JPH11510141A (ja) 1999-09-07

Similar Documents

Publication Publication Date Title
CA2575902C (en) Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide
US5861406A (en) Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
US5643915A (en) Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
Brown Matrix metalloproteinase inhibitors: a novel class of anticancer agents
US20040152745A1 (en) Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
US6265427B1 (en) Pharmaceutical composition for the method of treating leukemia
EP1228061A1 (en) Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
JP5806210B2 (ja) 癌または前癌状態を治療するための組み合わせ方法
MXPA98000998A (en) Use of fluconazole to inhibit the growth of cance
Elrod et al. The effects of statins on endothelium, inflammation and cardioprotection
MXPA98000944A (es) Uso de derivados de 1h-1,2,4-triazol para inhibirel crecimiento de canceres
US20200368180A1 (en) Deacetylnemorone Abietane Diterpenoids for Use in Cancer Treatment
US4620973A (en) Use of nootropics
US4940723A (en) Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat arthritis
EP0409845A1 (en) Method for protection from chemotherapeutic side effects
US6214824B1 (en) Use of amiloride for treating cancer
Siemann et al. Cell survival recovery kinetics in the KHT sarcoma following treatment with five alkylating agents and misonidazole
Niwa et al. Effect of a dihydropyridine analogue, 2-[benzyl (phenyl) amino] ethyl 1, 4-dihydro-2, 6-dimethyl-5-(5, 5-dimethyl-2-oxo-1, 3, 2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin
WO2005117864A1 (en) Combination product comprising anastrozole and a dual prenyl transferase inhibitor
WO2004037286A2 (en) Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof
Suto Radiosensitizers
Christensen et al. Reversal of multidrug resistance by derivatives of acrivastine
Freitas et al. Permeability Is Prevented by Simvastatin
Takao et al. Effect ofaDihydropyridine Analogue, 2-[Benzyl (phenyl) amino] ethyl l, 4-Dihydro-2, 6-dimethyl-5-(5, 5-dimethyl-2-oxo-l, 3, 2-dioxaphosphorinan-2-yl)-l-(2-morpholino-ethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on Reversing in Vivo Resistance of Tumor Cells to Adriamycin1
JPH03161437A (ja) 癌転移抑制剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160718